Hospital
Los Robles Regional Medical Center
Los Robles Regional Medical Center was paid $19.54M by Medicaid between Jan 2018 and Nov 2024, across 147 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 29% of everything it billed.
33Billing provider infoLOS ROBLES REGIONAL MEDICAL CENTER
THOUSAND OAKS, CA 91360
THOUSAND OAKS, CA 91360
33aNPI1306890389assigned 05/22/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$19.54M
24GClaims396,008
24DCodes billed147
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#125 of 410
Median peer was paid$6.90M
This provider vs. median2.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 77,844 | $2.62M | |
| 2019 | 71,744 | $2.84M | |
| 2020 | 58,118 | $2.25M | |
| 2021 | 48,698 | $2.84M | |
| 2022 | 51,998 | $3.38M | |
| 2023 | 55,533 | $3.43M | |
| 2024incomplete | 32,073 | $2.19M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 29% | 18,411 | 16,850 | $5.70M |
| A4649 | Surgical supply; miscellaneous | 17% | 43,141 | 17,998 | $3.30M |
| 0450 | Emergency room services | 15% | 30,293 | 26,959 | $2.84M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 9.0% | 1,134 | 1,070 | $1.76M |
| J3490 | Unclassified drugs | 7.1% | 7,382 | 5,975 | $1.40M |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.3% | 7,813 | 6,577 | $846K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.0% | 8,892 | 8,225 | $586K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.9% | 4,408 | 3,546 | $373K |
| 36415 | Collection of venous blood by venipuncture | 1.9% | 8,998 | 8,213 | $367K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 13,226 | 12,447 | $212K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,794 | 1,752 | $185K |
| 80053 | Comprehensive metabolic panel | <1% | 23,678 | 20,262 | $145K |
135 more codes
| 0270 | <1% | 1,700 | $121K | |
| 0160 | <1% | 585 | $114K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,818 | $114K |
| 99283 | Emergency room visit (moderate) | <1% | 2,776 | $111K |
| G0378 | Hospital observation service, per hour | <1% | 743 | $107K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,047 | $75K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,884 | $72K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 689 | $70K |
| 81001 | <1% | 10,649 | $66K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,564 | $63K |
| 99284 | Emergency room visit (serious) | <1% | 2,756 | $47K |
| 0250 | <1% | 3,282 | $44K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 697 | $39K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,994 | $36K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,509 | $34K |
| 80047 | <1% | 491 | $33K | |
| 85027 | <1% | 26,737 | $30K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,095 | $30K |
| 73630 | <1% | 698 | $28K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,540 | $28K |
| 73610 | <1% | 695 | $26K | |
| 99285 | Emergency room visit (most serious) | <1% | 697 | $24K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,040 | $22K |
| 87077 | <1% | 1,562 | $20K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,075 | $20K |
| 0272 | <1% | 3,089 | $19K | |
| 87070 | <1% | 272 | $18K | |
| 73562 | <1% | 597 | $18K | |
| 87486 | <1% | 1,515 | $17K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 841 | $17K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,401 | $17K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 438 | $17K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 475 | $16K |
| 82077 | <1% | 1,055 | $14K | |
| 86850 | <1% | 719 | $14K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,058 | $14K |
| 83880 | <1% | 5,589 | $12K | |
| 87081 | <1% | 432 | $12K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,988 | $11K |
| 73130 | <1% | 360 | $11K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,464 | $11K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 299 | $10K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,638 | $10K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,230 | $9K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 315 | $8K |
| 74018 | <1% | 295 | $8K | |
| 84484 | <1% | 6,916 | $8K | |
| 73110 | <1% | 217 | $8K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,007 | $7K |
| 73030 | <1% | 319 | $7K | |
| 87430 | <1% | 539 | $6K | |
| 83735 | <1% | 6,382 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,497 | $5K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,478 | $5K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,681 | $5K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 425 | $5K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 216 | $5K |
| 76830 | Ultrasound, transvaginal | <1% | 505 | $4K |
| 85610 | <1% | 7,057 | $4K | |
| 84703 | <1% | 4,946 | $4K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 178 | $4K |
| 83690 | <1% | 7,482 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 375 | $4K |
| 73140 | <1% | 25 | $3K | |
| 72110 | <1% | 68 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,549 | $3K |
| 87040 | <1% | 2,398 | $3K | |
| 93017 | <1% | 56 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,355 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,676 | $3K |
| 70496 | <1% | 127 | $3K | |
| 82330 | <1% | 1,728 | $2K | |
| 0258 | <1% | 541 | $2K | |
| 83605 | <1% | 2,143 | $2K | |
| 87581 | <1% | 1,514 | $2K | |
| 86140 | <1% | 1,800 | $2K | |
| 93971 | <1% | 174 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,131 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,314 | $2K |
| 85730 | <1% | 2,062 | $2K | |
| 82150 | <1% | 3,001 | $2K | |
| 87186 | <1% | 1,193 | $1K | |
| 0710 | <1% | 114 | $1K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 125 | $1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 89 | $1K |
| 0360 | <1% | 26 | $1K | |
| 74019 | <1% | 28 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 776 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,913 | $1K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,786 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 430 | $963.71 |
| 84702 | <1% | 591 | $941.76 | |
| 70498 | <1% | 100 | $911.39 | |
| 86900 | <1% | 1,254 | $904.35 | |
| 87252 | <1% | 29 | $885.00 | |
| 90715 | <1% | 282 | $880.61 | |
| 76801 | <1% | 83 | $861.11 | |
| 72170 | <1% | 77 | $806.26 | |
| 84100 | <1% | 756 | $798.56 | |
| 84145 | <1% | 834 | $792.59 | |
| 80329 | <1% | 1,055 | $763.70 | |
| 82550 | <1% | 535 | $692.92 | |
| 86901 | <1% | 1,244 | $677.19 | |
| 82248 | <1% | 1,287 | $649.42 | |
| 73502 | <1% | 14 | $645.18 | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 13 | $583.00 |
| 94729 | <1% | 14 | $580.55 | |
| 94726 | <1% | 14 | $579.25 | |
| 96376 | <1% | 1,425 | $571.36 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 43 | $499.85 |
| 93970 | <1% | 12 | $452.54 | |
| 80061 | Lipid panel | <1% | 285 | $393.79 |
| 82553 | <1% | 355 | $382.58 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 747 | $371.67 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 898 | $354.56 |
| 85652 | <1% | 539 | $328.85 | |
| 85651 | <1% | 665 | $297.22 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 17 | $289.98 |
| 80320 | <1% | 124 | $272.48 | |
| 85379 | <1% | 242 | $253.70 | |
| 84439 | <1% | 133 | $246.28 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 95 | $160.30 |
| A9270 | Non-covered item or service | <1% | 4,659 | $158.17 |
| 97163 | <1% | 12 | $111.57 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 85 | $82.53 |
| 73590 | <1% | 26 | $77.55 | |
| J1815 | Injection, insulin, per 5 units | <1% | 30 | $47.31 |
| S0028 | Injection, famotidine, 20 mg | <1% | 152 | $46.06 |
| 83874 | <1% | 12 | $30.68 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 493 | $28.93 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 16 | $27.06 |
| 0636 | <1% | 1,784 | $15.76 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 14 | $0.34 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 13 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMYERS, TIMOTHY (CFO)